4/24/2018
Pfizer has granted FDA Breakthrough Therapy designation for Trumenba, their Meningococcal Group B Vaccine. Pfizer Inc. announced today this Breakthrough Therapy designation from the FDA for active immunization to prevent invasive disease caused by Neisseria meningitites group B (MenB ) in children 1 through 9 years. This is the first Breakthrough Therapy designation for a MenB vaccine to help protect children as young as 1 year of age. Read press release.